Europe's Agrifood Innovation Edge Is Slipping Away

Jan de Vries · 2026-10-30

The Netherlands has built a reputation as Europe's agrifood powerhouse. But a new report from Invest-NL, the country's national investment institution, suggests that crown might be slipping. The report, called Deep Dive Agrifood Biotech, warns that while the Netherlands still excels at generating ideas, it's falling behind on turning those ideas into world-class companies. And the stakes? Roughly $18.5 billion in additional annual revenue by 2040—if the right moves are made now. ### A Strong Start, But a Weak Finish The Netherlands is home to top-tier agricultural research institutions, established seed breeders, and a sophisticated food production ecosystem. So why isn't that scientific excellence translating into globally competitive businesses? The report points to a telling imbalance: the Netherlands accounts for 3.3% of biotech startups worldwide, but only 1.3% of scale-ups. That gap suggests the country is great at starting companies—and less great at helping them grow. Invest-NL identifies three recurring weaknesses: - Too few promising technologies become scalable ventures. - Regulatory and validation processes delay market entry. - Insufficient financing prevents companies from reaching industrial production. In a favorable scenario, Dutch agrifood biotech revenues could reach about $27 billion annually by 2040. Under current conditions, they'd likely stall at just $8.5–9.7 billion. That's a massive difference—and a lot of value that could be captured elsewhere. Crucially, the report argues the Netherlands doesn't need to manufacture everything domestically. Instead, it should focus on retaining strategically valuable knowledge, intellectual property, companies, and specialized capabilities, while tapping into European production networks where it makes sense. ### Ten Years to Say Yes One of the most striking obstacles concerns biological crop protection—alternatives to conventional chemical pesticides. Getting European regulatory approval for a new biological crop protection product can take eight to ten years. Existing frameworks were largely designed for chemicals, making them a poor fit for certain biological innovations. As a result, some companies prioritize launching in markets like Brazil and the United States, where commercialization moves faster. Invest-NL warns that Europe risks losing ground in a biological crop protection market that could expand seven- to tenfold by 2040. Food biotechnology faces similar hurdles. Regulatory approval for novel ingredients can take one to three years longer in Europe than in the US, while building a first commercial production facility can require tens or even hundreds of millions of dollars. For fermentation-derived food ingredients alone, Invest-NL estimates that favorable conditions could support about $8.7 billion in annual Dutch revenues by 2040, compared with around $2.2 billion under existing policies. The report stresses that faster approvals shouldn't come at the expense of safety. Instead, regulators should offer earlier guidance, more predictable assessments, and opportunities for companies to validate products under real-world conditions. ### What's at Stake for Founders and Investors If you're building or funding an agrifood startup in Europe, this report is a wake-up call. The window to commercialize is narrowing, and other regions are moving faster. The Netherlands—and Europe more broadly—has the talent and the research base. But without coordinated action on regulation, financing, and commercialization, the next big agrifood breakthrough might just happen somewhere else. As Invest-NL puts it, innovation isn't the issue. The issue is scaling it.